Daily intelligence on the peptide research industry.

Research Pipeline

Retatrutide: What the TRIUMPH-1 Phase 3 Data and NDA Timeline Mean for Peptide Research Procurement

Eli Lilly's triple-agonist retatrutide posted a 28.3% average weight loss at 80 weeks in the Phase 3 TRIUMPH-1 trial — the largest efficacy signal ever recorded in a randomised obesity study. With an NDA submission targeted for Q4 2026 and a grey market already active, procurement teams need to understand what the compound is, where it stands legally, and how to source it responsibly for legitimate research.

25 Jun 2026

Research Pipeline

Semax: The Russian-Approved Neuropeptide Now at the Centre of the FDA's July 2026 Compounding Review

Semax, a synthetic ACTH-derived heptapeptide approved in Russia for stroke recovery and cognitive impairment, was removed from the FDA's Category 2 restricted compounding list in April 2026 and is now scheduled for formal PCAC review on 24 July 2026. For UK research-procurement teams, its regulatory trajectory — and the evidentiary questions the advisory panel must resolve — make it one of the more consequential peptides to monitor this summer.

01 Jun 2026

Research Pipeline

Oral Peptide Therapeutics Reach an Inflection Point: ICOTYDE's Approval, Pinnacle's $89M Raise, and What the Delivery Revolution Means for Research Labs

The FDA approval of icotrokinra (ICOTYDE) as the first targeted oral peptide to block the IL-23 receptor marks a structural shift in peptide drug delivery. Combined with a wave of investment in oral-peptide platforms and an upcoming PCAC advisory meeting, the field is entering a period of rapid technical and regulatory change that procurement teams need to understand.

29 May 2026

Research Pipeline

What the 2026 Orthopaedic Literature Says About Research Peptides — and Why It Matters for Procurement

A peer-reviewed review in JAAOS: Global Research & Reviews has systematically mapped the mechanism and evidence base for BPC-157, TB-500, GHK-Cu, Ipamorelin, CJC-1295 and related compounds in musculoskeletal medicine. The findings underscore a persistent gap between preclinical promise and human trial data — a distinction that carries direct implications for research-procurement professionals sourcing these compounds and for how suppliers should frame their documentation.

28 May 2026

Research Pipeline

Thymosin Alpha-1: The Peptide With the Strongest Clinical Evidence Base — and a Complicated Regulatory Story

Thymosin alpha-1 (Tα1) is approved as a prescription drug in more than 35 countries and has been evaluated in over 80 clinical trials. Yet its US compounding status remains unsettled, and a large 2025 phase 3 trial returned a negative primary endpoint in sepsis. For UK research-procurement professionals, it is arguably the most evidence-rich peptide on the market — and among the most instructive in understanding how clinical nuance shapes regulatory outcome.

24 May 2026

Research Pipeline

GHK-Cu: The Copper Tripeptide Facing Its Second Regulatory Wave — What Research Labs Need to Know

GHK-Cu (copper tripeptide-1) has one of the stronger mechanistic evidence bases among research peptides, spanning wound healing, collagen remodelling, and genomic modulation of over a thousand genes. Following the FDA's April 2026 Federal Register notice, it now sits in the second wave of PCAC review, scheduled before February 2027. This briefing covers its biochemistry, the state of the clinical evidence, and what the split regulatory picture means for UK procurement teams.

24 May 2026

Research Pipeline

TRIUMPH-4 read-out: retatrutide hits 28.7% weight loss but a new dysesthesia signal complicates the path to filing

Eli Lilly's triple-agonist retatrutide produced the highest weight-loss percentage ever recorded in a Phase 3 obesity trial in TRIUMPH-4, but a new dysesthesia signal — not seen in Phase 2 — affected one in five patients on the top dose. With seven further Phase 3 read-outs scheduled across 2026, the next nine months will determine whether retatrutide rewrites the GLP-1 competitive map or carries a safety footnote into the label.

18 May 2026

Research Pipeline

Foundayo (Orforglipron) Sustains Most Injectable GLP-1 Weight Loss in Phase 3b Switch Trial, New Data Show

A Phase 3b trial published in Nature Medicine on 12 May 2026 shows that patients who switched from injectable tirzepatide or semaglutide to once-daily oral orforglipron (Foundayo) retained 75–79% of their prior weight loss over 52 weeks. The data, presented simultaneously at the European Congress on Obesity, add clinical depth to an already-approved drug and sharpen the debate over whether oral small-molecule GLP-1 agonists can serve as maintenance therapy after injectable induction.

15 May 2026

Research Pipeline

Oral Small-Molecule GLP-1 Drugs Reach Deep Brain Reward Circuits, Pointing Towards Addiction Research Applications

A Nature study published 6 May 2026 found that oral small-molecule GLP-1 receptor agonists, including orforglipron and danuglipron, suppress hedonic feeding in mice by modulating a reward circuit in the central amygdala — a mechanism distinct from the hypothalamic appetite pathways activated by peptide-based GLP-1 drugs. The findings add mechanistic weight to a growing body of evidence linking GLP-1 pharmacology to reduced substance use disorder risk.

08 May 2026

Research Pipeline

MOTS-c: The Mitochondrial Peptide Generating Research Interest in Metabolic Disease and Ageing

MOTS-c is a 16-amino-acid peptide encoded not by the nuclear genome but by the mitochondrial genome, placing it in a distinct class from most research peptides. Growing preclinical data point to roles in glucose metabolism, insulin sensitivity, muscle preservation and β-cell protection, though no approved therapeutic use exists and regulatory status in both the US and UK remains firmly research-only.

08 May 2026